KALVISTA PHARMACEUTICALS INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
KALVISTA PHARMACEUTICALS INC. - More news...
KALVISTA PHARMACEUTICALS INC. - More news...
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
- KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program
- KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
- KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference
- KalVista Pharmaceuticals Announces Changes to Board of Directors
- KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900
- KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
- KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients
- KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
- KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
- KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
